These 8 new drugs are on the list of important medical progress in 2021!

At the China Medical Development Conference, the Chinese Academy of Medical Sciences released 31 important medical advances in China in 2021, including 7 in the field of clinical medicine, 1 in the field of stomatology, 8 in the field of basic medicine and biology, 8 in the field of pharmacy, and 8 in the field of health care.

In terms of pharmacy, 8 new drugs approved in 2021 are on the list , namely Tengsheng Biopharmaceutical Ambavirumab/Romisevirumab, Real Bio Azvudine, Hengrui Medicine Haitrapopaethanolamine, Hisun Pharmaceutical Haibo Maibu, Ascentage Medicine Orebatinib, Chi-Med Sivotinib, Zejing Biopharmaceutical Donafenib Tosylate, and Rongchang Biotech Vidicitumumab

June 2021

Vidicitumab

Vidicitumab is an innovative antibody-drug conjugate (ADC) independently developed by Rongchang Bio, which contains a HER2 antibody part, a linker and a cytotoxic drug monomethyl auristatin E (MMAE).

Donafenib Tosylate

Donafenib tosylate is an oral multi-target, multi-kinase inhibitor small molecule anti-tumor drug, approved in June 2021 for patients with unresectable hepatocellular carcinoma who have not received systemic therapy before

Hetrombopag ethanolamine tablets

Hetrombopag is an orally absorbed small-molecule non-peptide thrombopoietin receptor (TPO-R) agonist, which was approved for priority review in June 2021 for increased bleeding risk due to thrombocytopenia and clinical conditions Adult patients with chronic primary immune thrombocytopenia (ITP) who have not responded well to glucocorticoids, immunoglobulins, etc.

savatinib

Sevolitinib (formerly known as savolitinib) is a potent and highly selective oral MET tyrosine kinase inhibitor.

Haibo Maibu

The same mechanism as the marketed ezetimibe acts on the Niemann-Pick C1 class 1 (NPC1L1) protein receptor on the surface of intestinal and hepatocytes to selectively inhibit the absorption of cholesterol, passed in June 2021 Priority review was granted for the treatment of primary hypercholesterolemia

July 2021

Azvudine

Azvudine is the world's first dual-target inhibitor targeting HIV reverse transcriptase and the accessory protein Vif.

November 2021

Orebatinib

Orebatinib is a novel, third-generation BCR-ABL tyrosine kinase inhibitor (TKI) that was granted priority review in November 2021 and was conditionally approved for the treatment of resistance to any TKI with a well-validated The detection method is used to diagnose adult patients with chronic myeloid leukemia (CML) with T315I mutation in the chronic phase and accelerated phase

December 2021

Ambavirumab/Romisevirumab

In December 2021, the State Food and Drug Administration issued an emergency approval to Tengsheng Biopharmaceutical Holding Company, Tengsheng Huachuang Pharmaceutical Technology (Beijing) Co.